1
|
Reshetnyak T, Nurbaeva K, Ptashnik I, Kudriaeva A, Belogurov A, Lila A, Nasonov E. Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Int J Mol Sci 2023; 24:ijms24119210. [PMID: 37298160 DOI: 10.3390/ijms24119210] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 05/11/2023] [Accepted: 05/18/2023] [Indexed: 06/12/2023] Open
Abstract
Neutrophil Extracellular Traps (NETs) have been implicated in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) pathogenesis. The myeloperoxidase-deoxyribonucleic acid (MPO-DNA) complex and nucleosomes are serum markers of NETosis. The aim of this study was to assess these NETosis parameters as markers for SLE and APS diagnosis and their association with clinical features and disease activity. A total of 138 people were included in the cross-sectional study: 30 with SLE without APS, 47 with SLE and APS, 41 patients with primary antiphospholipid syndrome (PAPS), and 20 seemingly healthy individuals. Serum MPO-DNA complex and nucleosome levels were determined via an enzyme-linked immunosorbent assay (ELISA). Informed consent was obtained from all subjects involved in the study. The Ethics Committee of the V.A. Nasonova Research Institute of Rheumatology (Protocol No. 25 dated 23 December 2021) approved the study. In patients with SLE without APS, the levels of the MPO-DNA complex were significantly higher compared to patients with SLE with APS, with PAPS, and healthy controls (p < 0.0001). Among patients with a reliable diagnosis of SLE, 30 had positive values of the MPO-DNA complex, of whom 18 had SLE without APS, and 12 had SLE with APS. Patients with SLE and positive MPO-DNA complex levels were significantly more likely to have high SLE activity (χ2 = 5.25, p = 0.037), lupus glomerulonephritis (χ2 = 6.82, p = 0.009), positive antibodies to dsDNA (χ2 = 4.82, p = 0.036), and hypocomplementemia (χ2 = 6.72, p = 0.01). Elevated MPO-DNA levels were observed in 22 patients with APS: 12 with SLE with APS and 10 with PAPS. There were no significant associations between positive levels of the MPO-DNA complex and clinical and laboratory manifestations of APS. The concentration of nucleosomes was significantly lower in the group of SLE patients (±APS) compared to controls and PAPS (p < 0.0001). In SLE patients, the frequency of low nucleosome levels was associated with high SLE activity (χ2 = 13.4, p < 0.0001), lupus nephritis (χ2 = 4.1, p = 0.043), and arthritis (χ2 = 3.89, p = 0.048). An increase in the specific marker of NETosis, the MPO-DNA complex, was found in the blood serum of SLE patients without APS. Elevated levels of the MPO-DNA complex can be regarded as a promising biomarker of lupus nephritis, disease activity, and immunological disorders in SLE patients. Lower levels of nucleosomes were significantly associated with SLE (±APS). Low nucleosome levels were more common in patients with high SLE activity, lupus nephritis, and arthritis.
Collapse
Affiliation(s)
- Tatiana Reshetnyak
- V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia
- Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia
| | - Kamila Nurbaeva
- V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia
- Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia
| | - Ivan Ptashnik
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia
| | - Anna Kudriaeva
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia
- Department of Biological Chemistry, Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russian Federation, 127473 Moscow, Russia
| | - Aleksandr Lila
- V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia
- Department of Rheumatology, The Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia
| | - Evgeny Nasonov
- V.A. Nasonova Research Institute of Rheumatology, 115522 Moscow, Russia
| |
Collapse
|
2
|
Spallone A, Visocchi M, Greco F, Signorelli F, Gladi M, Fasinella R, Belogurov A, Iacoangeli M. Costotransversectomy in the Surgical Treatment of Mediolateral Thoracic Disk Herniations: Long-Term Results and Recent Minimally Invasive Technical Adjuncts. Acta Neurochir Suppl 2023; 135:375-383. [PMID: 38153496 DOI: 10.1007/978-3-031-36084-8_57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2023]
Abstract
Thoracic herniated disks are relatively rare. They account for approximately 2% of all intervertebral herniated disks in large series. Traditional surgery via laminectomy has frequently yielded disappointing results, although the recent literature reports that anterior calcified thoracic herniation was successfully treated with this approach. This issue has encouraged a search for alternatives, such as anterolateral, lateral, and posterolateral approaches to the thoracic spine. From January 2009 to December 2019, we selected 66 patients harboring a symptomatic median-paramedian herniated disk at the level of the thoracic spine, treated at the authors' institutions. The present experience would give further support to the use of costotrasversectomy, along with its "mini-invasive" modifications, as a suitable and safe approach for thoracic disk disease. Although we must admit that endoscopy is likely to become the gold standard of surgical method in the future and that the anterior approach with mini-toracotomy without rib removal will become popular, the future scenario could certainly reserve an important place for the approach we have used in the surgical management of this challenging spinal pathology, mainly because of the approach's versatility and short learning curve.
Collapse
Affiliation(s)
- Aldo Spallone
- Institute of Bioorganic Chemistry, Neuroscience, Russian Academy of Sciences, Moscow, Russia
- NCL-Neurological Center of Latium, Rome, Italy
| | | | - Fabio Greco
- Skull Base Surgery Unit, Campus Bio-Medico University, Rome, Italy
| | - Francesco Signorelli
- Institute of Neurosurgery, Le Marche Polytechnic University and Polyclinic, Ancona, Italy
| | - Maurizio Gladi
- Institute of Bioorganic Chemistry, Neuroscience, Russian Academy of Sciences, Moscow, Russia
- NCL-Neurological Center of Latium, Rome, Italy
| | - Rossella Fasinella
- Institute of Bioorganic Chemistry, Neuroscience, Russian Academy of Sciences, Moscow, Russia
- NCL-Neurological Center of Latium, Rome, Italy
| | - Alexey Belogurov
- Institute of Bioorganic Chemistry, Neuroscience, Russian Academy of Sciences, Moscow, Russia
- NCL-Neurological Center of Latium, Rome, Italy
| | - Maurizio Iacoangeli
- Institute of Bioorganic Chemistry, Neuroscience, Russian Academy of Sciences, Moscow, Russia.
- NCL-Neurological Center of Latium, Rome, Italy.
| |
Collapse
|
3
|
Terekhov SS, Mokrushina YA, Nazarov AS, Zlobin A, Zalevsky A, Bourenkov G, Golovin A, Belogurov A, Osterman IA, Kulikova AA, Mitkevich VA, Lou HJ, Turk BE, Wilmanns M, Smirnov IV, Altman S, Gabibov AG. A kinase bioscavenger provides antibiotic resistance by extremely tight substrate binding. Sci Adv 2020; 6:eaaz9861. [PMID: 32637600 PMCID: PMC7314540 DOI: 10.1126/sciadv.aaz9861] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Accepted: 04/16/2020] [Indexed: 06/11/2023]
Abstract
Microbial communities are self-controlled by repertoires of lethal agents, the antibiotics. In their turn, these antibiotics are regulated by bioscavengers that are selected in the course of evolution. Kinase-mediated phosphorylation represents one of the general strategies for the emergence of antibiotic resistance. A new subfamily of AmiN-like kinases, isolated from the Siberian bear microbiome, inactivates antibiotic amicoumacin by phosphorylation. The nanomolar substrate affinity defines AmiN as a phosphotransferase with a unique catalytic efficiency proximal to the diffusion limit. Crystallographic analysis and multiscale simulations revealed a catalytically perfect mechanism providing phosphorylation exclusively in the case of a closed active site that counteracts substrate promiscuity. AmiN kinase is a member of the previously unknown subfamily representing the first evidence of a specialized phosphotransferase bioscavenger.
Collapse
Affiliation(s)
- Stanislav S. Terekhov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| | - Yuliana A. Mokrushina
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| | - Anton S. Nazarov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
| | - Alexander Zlobin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia
| | - Arthur Zalevsky
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia
- Sechenov First Moscow State Medical University, Institute of Molecular Medicine, Moscow, Russia
| | | | - Andrey Golovin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia
- Sechenov First Moscow State Medical University, Institute of Molecular Medicine, Moscow, Russia
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
| | - Ilya A. Osterman
- Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
- Skolkovo Institute of Science and Technology, Skolkovo, Russia
| | - Alexandra A. Kulikova
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
| | - Vladimir A. Mitkevich
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
| | - Hua Jane Lou
- Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA
| | - Benjamin E. Turk
- Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA
| | | | - Ivan V. Smirnov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
| | - Sidney Altman
- Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA
- Arizona State University, Tempe, AZ, USA
| | - Alexander G. Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
- Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia
- Department of Life Sciences, Higher School of Economics, Moscow, Russia
| |
Collapse
|
4
|
Mamedov A, Vorobyeva N, Filimonova I, Zakharova M, Kiselev I, Bashinskaya V, Baulina N, Boyko A, Favorov A, Kulakova O, Ziganshin R, Smirnov I, Poroshina A, Shilovskiy I, Khaitov M, Sykulev Y, Favorova O, Vlassov V, Gabibov A, Belogurov A. Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides. Front Immunol 2020; 10:3088. [PMID: 32010139 PMCID: PMC6978714 DOI: 10.3389/fimmu.2019.03088] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Accepted: 12/17/2019] [Indexed: 12/15/2022] Open
Abstract
Risk of the development of multiple sclerosis (MS) is known to be increased in individuals bearing distinct class II human leukocyte antigen (HLA) variants, whereas some of them may have a protective effect. Here we analyzed distribution of a highly polymorphous HLA-DRB1 locus in more than one thousand relapsing-remitting MS patients and healthy individuals of Russian ethnicity. Carriage of HLA-DRB1*15 and HLA-DRB1*03 alleles was associated with MS risk, whereas carriage of HLA-DRB1*01 and HLA-DRB1*11 was found to be protective. Analysis of genotypes revealed the compensatory effect of risk and resistance alleles in trans. We have identified previously unknown MBP153-161 peptide located at the C-terminus of MBP protein and MBP90-98 peptide that bound to recombinant HLA-DRB1*01:01 protein with affinity comparable to that of classical antigenic peptide 306-318 from the hemagglutinin (HA) of the influenza virus demonstrating the ability of HLA-DRB1*01:01 to present newly identified MBP153-161 and MBP90-98 peptides. Measurements of kinetic parameters of MBP and HA peptides binding to HLA-DRB1*01:01 catalyzed by HLA-DM revealed a significantly lower rate of CLIP exchange for MBP153-161 and MBP90-98 peptides as opposed to HA peptide. Analysis of the binding of chimeric MBP-HA peptides demonstrated that the observed difference between MBP153-161, MBP90-98, and HA peptide epitopes is caused by the lack of anchor residues in the C-terminal part of the MBP peptides resulting in a moderate occupation of P6/7 and P9 pockets of HLA-DRB1*01:01 by MBP153-161 and MBP90-98 peptides in contrast to HA308-316 peptide. This leads to the P1 and P4 docking failure and rapid peptide dissociation and release of empty HLA-DM-HLA-DR complex. We would like to propose that protective properties of the HLA-DRB1*01 allele could be directly linked to the ability of HLA-DRB1*01:01 to kinetically discriminate between antigenic exogenous peptides and endogenous MBP derived peptides.
Collapse
Affiliation(s)
- Azad Mamedov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | | | - Ioanna Filimonova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Maria Zakharova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.,Pirogov Russian National Research Medical University, Moscow, Russia
| | - Ivan Kiselev
- Pirogov Russian National Research Medical University, Moscow, Russia
| | | | - Natalia Baulina
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - Alexey Boyko
- Pirogov Russian National Research Medical University, Moscow, Russia.,Neuroimmunological Department of the Federal Center of Cerebrovascular Diseases and Stroke, Moscow, Russia
| | - Alexander Favorov
- Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD, United States.,Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia
| | - Olga Kulakova
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - Rustam Ziganshin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Ivan Smirnov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.,Institute of Fundamental Medicine and Biology, Kazan (Volga) Federal University, Kazan, Russia
| | - Alina Poroshina
- National Research Center Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Igor Shilovskiy
- National Research Center Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Musa Khaitov
- National Research Center Institute of Immunology FMBA of Russia, Moscow, Russia
| | - Yuri Sykulev
- Department of Microbiology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Olga Favorova
- Pirogov Russian National Research Medical University, Moscow, Russia
| | - Valentin Vlassov
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia
| | - Alexander Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.,Department of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.,Department of Fundamental Medicine, Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
5
|
Affiliation(s)
- Anna Kudriaeva
- Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussian Federation
| | - Ekaterina S. Kuzina
- Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussian Federation
| | - Oleg Zubenko
- Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussian Federation
| | - Ivan V. Smirnov
- Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussian Federation
- Kazan Federal UniversityKazanRussian Federation
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussian Federation
- Department of Fundamental MedicineLomonosov Moscow State UniversityMoscowRussian Federation
| |
Collapse
|
6
|
Filippova A, Lyapina I, Kirov I, Zgoda V, Belogurov A, Kudriaeva A, Ivanov V, Fesenko I. Salicylic acid influences the protease activity and posttranslation modifications of the secreted peptides in the moss Physcomitrella patens. J Pept Sci 2018; 25:e3138. [PMID: 30575224 DOI: 10.1002/psc.3138] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 11/18/2018] [Accepted: 11/20/2018] [Indexed: 02/06/2023]
Abstract
Plant secretome comprises dozens of secreted proteins. However, little is known about the composition of the whole secreted peptide pools and the proteases responsible for the generation of the peptide pools. The majority of studies focus on target detection and characterization of specific plant peptide hormones. In this study, we performed a comprehensive analysis of the whole extracellular peptidome, using moss Physcomitrella patens as a model. Hundreds of modified and unmodified endogenous peptides that originated from functional and nonfunctional protein precursors were identified. The plant proteases responsible for shaping the pool of endogenous peptides were predicted. Salicylic acid (SA) influenced peptide production in the secretome. The proteasome activity was altered upon SA treatment, thereby influencing the composition of the peptide pools. These results shed more light on the role of proteases and posttranslational modification in the "active management" of the extracellular peptide pool in response to stress conditions. It also identifies a list of potential peptide hormones in the moss secretome for further analysis.
Collapse
Affiliation(s)
- Anna Filippova
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| | - Irina Lyapina
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| | - Ilya Kirov
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| | - Victor Zgoda
- V.N. Orekhovich Research Institute of Biomedical Chemistry, Department of Proteomic Research and Mass Spectrometry, Moscow, Russian Federation
| | - Alexey Belogurov
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| | - Anna Kudriaeva
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| | - Vadim Ivanov
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| | - Igor Fesenko
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
| |
Collapse
|
7
|
Lomakin Y, Kudriaeva A, Kostin N, Terekhov S, Kaminskaya A, Chernov A, Zakharova M, Ivanova M, Simaniv T, Telegin G, Gabibov A, Belogurov A. Diagnostics of autoimmune neurodegeneration using fluorescent probing. Sci Rep 2018; 8:12679. [PMID: 30139963 PMCID: PMC6107501 DOI: 10.1038/s41598-018-30938-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2018] [Accepted: 08/01/2018] [Indexed: 11/22/2022] Open
Abstract
The discovery of antibody-mediated catalysis was a breakthrough that showed antibody function is not limited to specific binding interactions, and that immunoglobulins (Igs) may also chemically transform their target antigens. Recently, so-called “natural catalytic antibodies” have been intimately linked with several pathologies, where they either protect the organism or contribute to the development of autoimmune abnormalities. Previously, we showed that myelin-reactive autoantibodies from patients with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE) exhibit the ability to recognize and hydrolyse distinct epitopes within myelin basic protein (MBP). Further, the antibody-mediated cleavage of encephalitogenic MBP peptide 81–103, flanked by two fluorescent proteins, can serve as a novel biomarker for MS. Here, we report the next generation of this biomarker, based on the antibody-mediated degradation of a novel chemically synthesized FRET substrate, comprising the fluorophore Cy5 and the quencher QXL680, interconnected by the MBP peptide 81–99: Cy5-MBP81–99-QXL680. This substrate is degraded upon incubation with either purified antibodies from MS patients but not healthy donors or purified antibodies and splenocytes from EAE but not from non-immunized mice. Data presented herein suggest the elaboration of potential specific, rapid, and sensitive diagnostic criteria of active progressive MS.
Collapse
Affiliation(s)
- Yakov Lomakin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Anna Kudriaeva
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | - Nikita Kostin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | - Stanislav Terekhov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | - Alena Kaminskaya
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | - Alexander Chernov
- Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Pushchino, Russia
| | - Maria Zakharova
- Neurorehabilitation Department of the Research Center of Neurology, Moscow, Russia
| | - Maria Ivanova
- Neurorehabilitation Department of the Research Center of Neurology, Moscow, Russia
| | - Taras Simaniv
- Neurorehabilitation Department of the Research Center of Neurology, Moscow, Russia
| | - Georgy Telegin
- Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Pushchino, Russia
| | - Alexander Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia. .,Lomonosov Moscow State University, Moscow, Russia.
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia. .,Lomonosov Moscow State University, Moscow, Russia.
| |
Collapse
|
8
|
Zlobin A, Mokrushina Y, Terekhov S, Zalevsky A, Bobik T, Stepanova A, Aliseychik M, Kartseva O, Panteleev S, Golovin A, Belogurov A, Gabibov A, Smirnov I. QM/MM Description of Newly Selected Catalytic Bioscavengers Against Organophosphorus Compounds Revealed Reactivation Stimulus Mediated by Histidine Residue in the Acyl-Binding Loop. Front Pharmacol 2018; 9:834. [PMID: 30123127 PMCID: PMC6085465 DOI: 10.3389/fphar.2018.00834] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Accepted: 07/11/2018] [Indexed: 11/14/2022] Open
Abstract
Butyrylcholinesterase (BChE) is considered as an efficient stoichiometric antidote against organophosphorus (OP) poisons. Recently we utilized combination of calculations and ultrahigh-throughput screening (uHTS) to select BChE variants capable of catalytic destruction of OP pesticide paraoxon. The purpose of this study was to elucidate the molecular mechanism underlying enzymatic hydrolysis of paraoxon by BChE variants using hybrid quantum mechanical/molecular mechanical (QM/MM) calculations. Detailed analysis of accomplished QM/MM runs revealed that histidine residues introduced into the acyl-binding loop are always located in close proximity with aspartate residue at position 70. Histidine residue acts as general base thus leading to attacking water molecule activation and subsequent SN2 inline hydrolysis resulting in BChE reactivation. This combination resembles canonical catalytic triad found in active centers of various proteases. Carboxyl group activates histidine residue by altering its pKa, which in turn promotes the activation of water molecule in terms of its nucleophilicity. Observed re-protonation of catalytic serine residue at position 198 from histidine residue at position 438 recovers initial configuration of the enzyme’s active center, facilitating next catalytic cycle. We therefore suggest that utilization of uHTS platform in combination with deciphering of molecular mechanisms by QM/MM calculations may significantly improve our knowledge of enzyme function, propose new strategies for enzyme design and open new horizons in generation of catalytic bioscavengers against OP poisons.
Collapse
Affiliation(s)
- Alexander Zlobin
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia
| | - Yuliana Mokrushina
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Stanislav Terekhov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Arthur Zalevsky
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.,Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Tatiana Bobik
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Anastasiya Stepanova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Maria Aliseychik
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Olga Kartseva
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Sergey Panteleev
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Andrey Golovin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.,Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Alexey Belogurov
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.,Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.,Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russia
| | - Alexander Gabibov
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.,Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Ivan Smirnov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
9
|
Lomakin YA, Belogurov A. Exposure to the Epstein-Barr viral antigen induces affinity-maturated anti-myelin antibodies. The Journal of Immunology 2018. [DOI: 10.4049/jimmunol.200.supp.162.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Multiple Sclerosis (MS) is an autoimmune chronic inflammatory disease of central nervous system (CNS). Cross-reactivity of neuronal proteins with exogenous antigens is considered as one of the possible mechanisms of MS triggering. Previously we showed that monoclonal myelin basic protein (MBP)-specific IgGs are cross-reactive with Epstein-Barr virus (EBV) protein LMP-1. Here we report evidence that exposure of mice to LMP1 may result in induction of myelin-reactive autoantibodies in vivo. Only part of such anti-MBP antibodies are cross-reactive towards LMP1 but majority is occurred as a result of epitope spreading. We suggest that chronic contact with viral antigen rather than multiple rapid exposures to it is more sufficient in inducing switch of B cells from viral to myelin antigen. Moreover, even in inbred animals being almost identical in terms of genome, such switch was observed only in 20% of animals, indicating that this evidence is occurred by a chance rather than systematically. Our findings provide novel insights into still enigmatic link between EBV infection and MS development, determining several criteria that are beneficial for induction of self-reacting antibodies on the background of viral infection.
Current study was supported by Russian Science Foundation grant #17-74-30019.
Collapse
Affiliation(s)
| | - Alexey Belogurov
- 1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russia
| |
Collapse
|
10
|
Ivanova VV, Khaiboullina SF, Gomzikova MO, Martynova EV, Ferreira AM, Garanina EE, Sakhapov DI, Lomakin YA, Khaibullin TI, Granatov EV, Khabirov FA, Rizvanov AA, Gabibov A, Belogurov A. Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis. Front Immunol 2017; 8:1335. [PMID: 29085375 PMCID: PMC5650689 DOI: 10.3389/fimmu.2017.01335] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 10/03/2017] [Indexed: 11/13/2022] Open
Abstract
Multiple sclerosis (MS) is an autoimmune disease characterized by demyelination and consequent neuron injury. Although the pathogenesis of MS is largely unknown, a breach in immune self-tolerance to myelin followed by development of autoreactive encephalitogenic T cells is suggested to play the central role. The myelin basic protein (MBP) is believed to be one of the main targets for autoreactive lymphocytes. Recently, immunodominant MBP peptides encapsulated into the mannosylated liposomes, referred as Xemys, were shown to suppress development of experimental autoimmune encephalomyelitis, a rodent model of MS, and furthermore passed the initial stage of clinical trials. Here, we investigated the role of individual polypeptide components [MBP peptides 46-62 (GH17), 124-139 (GK16), and 147-170 (QR24)] of this liposomal peptide therapeutic in cytokine release and activation of immune cells from MS patients and healthy donors. The overall effects were assessed using peripheral blood mononuclear cells (PBMCs), whereas alterations in antigen-presenting capacities were studied utilizing plasmacytoid dendritic cells (pDCs). Among three MBP-immunodominant peptides, QR24 and GK16 activated leukocytes, while GH17 was characterized by an immunosuppressive effect. Peptides QR24 and GK16 upregulated CD4 over CD8 T cells and induced proliferation of CD25+ cells, whereas GH17 decreased the CD4/CD8 T cell ratio and had limited effects on CD25+ T cells. Accordingly, components of liposomal peptide therapeutic differed in upregulation of cytokines upon addition to PBMCs and pDCs. Peptide QR24 was evidently more effective in upregulation of pro-inflammatory cytokines, whereas GH17 significantly increased production of IL-10 through treated cells. Altogether, these data suggest a complexity of action of the liposomal peptide therapeutic that does not seem to involve simple helper T cells (Th)-shift but rather the rebalancing of the immune system.
Collapse
Affiliation(s)
- Vilena V Ivanova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Svetlana F Khaiboullina
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.,Department of Microbiology and Immunology, University of Nevada, Reno, NV, United States
| | - Marina O Gomzikova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Ekaterina V Martynova
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - André M Ferreira
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Ekaterina E Garanina
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Damir I Sakhapov
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Yakov A Lomakin
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.,Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | | | | | | | - Albert A Rizvanov
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
| | - Alexander Gabibov
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.,Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Lomonosov Moscow State University, Moscow, Russia
| | - Alexey Belogurov
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia.,Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
11
|
Lomakin Y, Arapidi GP, Chernov A, Ziganshin R, Tcyganov E, Lyadova I, Butenko IO, Osetrova M, Ponomarenko N, Telegin G, Govorun VM, Gabibov A, Belogurov A. Exposure to the Epstein-Barr Viral Antigen Latent Membrane Protein 1 Induces Myelin-Reactive Antibodies In Vivo. Front Immunol 2017; 8:777. [PMID: 28729867 PMCID: PMC5498468 DOI: 10.3389/fimmu.2017.00777] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Accepted: 06/19/2017] [Indexed: 11/30/2022] Open
Abstract
Multiple sclerosis (MS) is an autoimmune chronic inflammatory disease of the central nervous system (CNS). Cross-reactivity of neuronal proteins with exogenous antigens is considered one of the possible mechanisms of MS triggering. Previously, we showed that monoclonal myelin basic protein (MBP)-specific antibodies from MS patients cross-react with Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1). In this study, we report that exposure of mice to LMP1 results in induction of myelin-reactive autoantibodies in vivo. We posit that chronic exposure or multiple acute exposures to viral antigen may redirect B cells from production of antiviral antibodies to antibodies, specific to myelin antigen. However, even in inbred animals, which are almost identical in terms of their genomes, such an effect is only observed in 20–50% of animals, indicating that this change occurs by chance, rather than systematically. Cross-immunoprecipitation analysis showed that only part of anti-MBP antibodies from LMP1-immunized mice might simultaneously bind LMP1. In contrast, the majority of anti-LMP1 antibodies from MBP-immunized mice bind MBP. De novo sequencing of anti-LMP1 and anti-MBP antibodies by mass spectrometry demonstrated enhanced clonal diversity in LMP1-immunized mice in comparison with MBP-immunized mice. We suggest that induction of MBP-reactive antibodies in LMP1-immunized mice may be caused by either Follicular dendritic cells (FDCs) or by T cells that are primed by myelin antigens directly in CNS. Our findings help to elucidate the still enigmatic link between EBV infection and MS development, suggesting that myelin-reactive antibodies raised as a response toward EBV protein LMP1 are not truly cross-reactive but are primarily caused by epitope spreading.
Collapse
Affiliation(s)
- Yakov Lomakin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Institute of Fundamental Medicine and Biology, Kazan (Volga) Federal University, Kazan, Russia
| | - Georgii Pavlovich Arapidi
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Moscow Institute of Physics and Technology, Dolgoprudny, Russia
| | - Alexander Chernov
- Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Pushchino, Russia
| | - Rustam Ziganshin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | - Evgenii Tcyganov
- Department of Immunology, Central Tuberculosis Research Institute RAS, Moscow, Russia
| | - Irina Lyadova
- Department of Immunology, Central Tuberculosis Research Institute RAS, Moscow, Russia
| | | | - Maria Osetrova
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | | | - Georgy Telegin
- Branch of Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Pushchino, Russia
| | - Vadim Markovich Govorun
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Moscow Institute of Physics and Technology, Dolgoprudny, Russia.,Research Institute of Physical Chemical Medicine, Federal Medical and Biological Agency, Moscow, Russia
| | - Alexander Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Institute of Fundamental Medicine and Biology, Kazan (Volga) Federal University, Kazan, Russia.,Lomonosov Moscow State University, Moscow, Russia
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia.,Institute of Fundamental Medicine and Biology, Kazan (Volga) Federal University, Kazan, Russia.,Lomonosov Moscow State University, Moscow, Russia
| |
Collapse
|
12
|
Stepanov A, Lomakin Y, Gabibov A, Belogurov A. Peptides Against Autoimmune Neurodegeneration. Curr Med Chem 2017; 24:1761-1771. [PMID: 28578649 DOI: 10.2174/0929867324666170605092221] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 05/29/2017] [Accepted: 05/30/2017] [Indexed: 11/22/2022]
Abstract
The mammalian immune system is a nearly perfect defensive system polished by a hundred million years of evolution. Unique flexibility and adaptivity have created a virtually impenetrable barrier to numerous exogenous pathogens that are assaulting us every moment. Unfortunately, triggers that remain mostly enigmatic will sometimes persuade the immune system to retarget against self-antigens. This civil war remains underway, showing no mercy and taking no captives, eventually leading to irreversible pathological changes in the human body. Research that has emerged during the last two decades has given us hope that we may have a chance to overcome autoimmune diseases using a variety of techniques to "reset" the immune system. In this report, we summarize recent advances in utilizing short polypeptides - mostly fragments of autoantigens - in the treatment of autoimmune neurodegeneration.
Collapse
Affiliation(s)
- Alexey Stepanov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation
| | - Yakov Lomakin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation
| | - Alexander Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russian Federation
| | - Alexey Belogurov
- Shemyakin- Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Miklukho-Maklaya str., 16/10, Moscow, 117997, Russian Federation
| |
Collapse
|
13
|
Kudriaeva A, Galatenko VV, Maltseva DV, Khaustova NA, Kuzina E, Tonevitsky AG, Gabibov A, Belogurov A. The Transcriptome of Type I Murine Astrocytes under Interferon-Gamma Exposure and Remyelination Stimulus. Molecules 2017; 22:molecules22050808. [PMID: 28505143 PMCID: PMC6153759 DOI: 10.3390/molecules22050808] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Revised: 04/30/2017] [Accepted: 05/11/2017] [Indexed: 02/04/2023] Open
Abstract
Astrocytes are considered to be an important contributor to central nervous system (CNS) disorders, particularly multiple sclerosis. The transcriptome of these cells is greatly affected by cytokines released by lymphocytes, penetrating the blood–brain barrier—in particular, the classical pro-inflammatory cytokine interferon-gamma (IFNγ). We report here the transcriptomal profiling of astrocytes treated using IFNγ and benztropine, a putative remyelinization agent. Our findings indicate that the expression of genes involved in antigen processing and presentation in astrocytes are significantly upregulated upon IFNγ exposure, emphasizing the critical role of this cytokine in the redirection of immune response towards self-antigens. Data reported herein support previous observations that the IFNγ-induced JAK-STAT signaling pathway may be regarded as a valuable target for pharmaceutical interventions.
Collapse
Affiliation(s)
- Anna Kudriaeva
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
| | - Vladimir V Galatenko
- Department of Mathematical Analysis, Faculty of Mechanics and Mathematics, Lomonosov Moscow State University, 119991 Moscow, Russia.
- Big Data and Information Retrieval School, Faculty of Computer Science, National Research University Higher School of Economics, 125319 Moscow, Russia.
- SRC Bioclinicum, 115088 Moscow, Russia.
| | | | | | - Ekaterina Kuzina
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
| | | | - Alexander Gabibov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
- Big Data and Information Retrieval School, Faculty of Computer Science, National Research University Higher School of Economics, 125319 Moscow, Russia.
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
| | - Alexey Belogurov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
- Big Data and Information Retrieval School, Faculty of Computer Science, National Research University Higher School of Economics, 125319 Moscow, Russia.
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
| |
Collapse
|
14
|
Lomakin Y, Shmidt A, Glagoleva I, Okunola J, Vaskina M, Belogurov A, Gabibov A. Myelin-Reactive Monoclonal Antibodies from Multiple Sclerosis Patients Cross-React with Nucleoproteins in HEp-2 Lysate. BioNanoSci 2016. [DOI: 10.1007/s12668-016-0222-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
15
|
Belogurov A, Zakharov K, Lomakin Y, Surkov K, Avtushenko S, Kruglyakov P, Smirnov I, Makshakov G, Lockshin C, Gregoriadis G, Genkin D, Gabibov A, Evdoshenko E. CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study. Neurotherapeutics 2016; 13:895-904. [PMID: 27324388 PMCID: PMC5081122 DOI: 10.1007/s13311-016-0448-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Previously, we showed that CD206-targeted liposomal delivery of co-encapsulated immunodominant myelin basic protein (MBP) sequences MBP46-62, MBP124-139 and MBP147-170 (Xemys) suppressed experimental autoimmune encephalomyelitis in dark Agouti rats. The objective of this study was to assess the safety of Xemys in the treatment of patients with relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, who failed to achieve a sustained response to first-line disease-modifying therapies. In this phase I, open-label, dose-escalating, proof-of-concept study, 20 patients with relapsing-remitting or secondary progressive MS received weekly subcutaneously injections with ascending doses of Xemys up to a total dose of 2.675 mg. Clinical examinations, including Expanded Disability Status Scale score, magnetic resonance imaging results, and serum cytokine concentrations, were assessed before the first injection and for up to 17 weeks after the final injection. Xemys was safe and well tolerated when administered for 6 weeks to a maximum single dose of 900 μg. Expanded Disability Status Scale scores and numbers of T2-weighted and new gadolinium-enhancing lesions on magnetic resonance imaging were statistically unchanged at study exit compared with baseline; nonetheless, the increase of number of active gadolinium-enhancing lesions on weeks 7 and 10 in comparison with baseline was statistically significant. During treatment, the serum concentrations of the cytokines monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, and interleukin-7 decreased, whereas the level of tumor necrosis factor-α increased. These results provide evidence for the further development of Xemys as an antigen-specific, disease-modifying therapy for patients with MS.
Collapse
Affiliation(s)
- Alexey Belogurov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia
- Institute of Gene Biology RAS, Moscow, Russia
| | | | - Yakov Lomakin
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia
| | | | | | | | - Ivan Smirnov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia
| | - Gleb Makshakov
- Center of multiple sclerosis and AID of St. Petersburg City Clinical Hospital #31, St. Petersburg, Russia
- Pavlov First Saint-Petersburg State Medical University, St. Petersburg, Russia
| | | | | | | | - Alexander Gabibov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia.
- Chemistry Department of Moscow State University, Moscow, Russia.
| | - Evgeniy Evdoshenko
- Center of multiple sclerosis and AID of St. Petersburg City Clinical Hospital #31, St. Petersburg, Russia
- Pavlov First Saint-Petersburg State Medical University, St. Petersburg, Russia
- SBI "Center of Clinical Trials Management and Performance of Moscow Department of Healthcare", Moscow, Russia
| |
Collapse
|
16
|
Stepanov A, Belyy A, Kasheverov I, Rybinets A, Dronina M, Dyachenko I, Murashev A, Knorre V, Sakharov D, Ponomarenko N, Tsetlin V, Tonevitsky A, Deyev S, Belogurov A, Gabibov A. Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs. Biotechnol Lett 2016; 38:1173-80. [PMID: 27099070 DOI: 10.1007/s10529-016-2092-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 03/17/2016] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in multiple sclerosis (MS), therefore selective depletion of autoreactive lymphocytes exposing MOG-specific B cell receptors (BCRs) would be beneficial in terms of MS treatment. RESULTS Using E. coli we generated an efficient protocol for the purification of the recombinant immunotoxin DT-MOG composed of the extracellular Ig-like domain of MOG fused in frame with the catalytic and translocation subunits of diphtheria toxin (DT, Corynebacterium diphtheriae) under native conditions with a final yield of 1.5 mg per liter of culture medium. Recombinant DT-MOG was recognized in vitro by MOG-reactive antibodies and has catalytic activity comparable with wild-type DT. CONCLUSION Enhanced pharmacokinetics (mean residence time in the bloodstream of 61 min) and minimized diminished nonspecific toxicity (LD50 = 1.76 mg/kg) of the DT-MOG makes it a potential candidate for the immunotherapy of MS.
Collapse
Affiliation(s)
- Alexey Stepanov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997.,Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia
| | - Alexander Belyy
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997.,Department of Bacterial Infections, Gamaleya Research Institute, Gamaleya Str., 18, Moscow, Russia, 123098
| | - Igor Kasheverov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Alexandra Rybinets
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Maria Dronina
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Igor Dyachenko
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Arkady Murashev
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Vera Knorre
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Dmitry Sakharov
- SRC Bioclinicum, Ugreshskaya str 2/85, Moscow, Russia, 115088
| | - Natalya Ponomarenko
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Victor Tsetlin
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | | | - Sergey Deyev
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997
| | - Alexey Belogurov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997.,Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia
| | - Alexander Gabibov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, Russia, 117997. .,Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Tatarstan, Russia.
| |
Collapse
|
17
|
Terekhov S, Smirnov I, Bobik T, Shamborant O, Zenkova M, Chernolovskaya E, Gladkikh D, Murashev A, Dyachenko I, Palikov V, Palikova Y, Knorre V, Belogurov A, Ponomarenko N, Blackburn GM, Masson P, Gabibov A. A novel expression cassette delivers efficient production of exclusively tetrameric human butyrylcholinesterase with improved pharmacokinetics for protection against organophosphate poisoning. Biochimie 2015; 118:51-9. [DOI: 10.1016/j.biochi.2015.07.028] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2015] [Accepted: 07/30/2015] [Indexed: 10/23/2022]
|
18
|
Belogurov A, Kuzina E, Kudriaeva A, Kononikhin A, Kovalchuk S, Surina Y, Smirnov I, Lomakin Y, Bacheva A, Stepanov A, Karpova Y, Lyupina Y, Kharybin O, Melamed D, Ponomarenko N, Sharova N, Nikolaev E, Gabibov A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J 2015; 29:1901-13. [PMID: 25634956 PMCID: PMC4415016 DOI: 10.1096/fj.14-259333] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2014] [Accepted: 12/22/2014] [Indexed: 11/18/2022]
Abstract
Recent findings indicate that the ubiquitin–proteasome system is involved in the pathogenesis of cancer as well as autoimmune and several neurodegenerative diseases, and is thus a target for novel therapeutics. One disease that is related to aberrant protein degradation is multiple sclerosis, an autoimmune disorder involving the processing and presentation of myelin autoantigens that leads to the destruction of axons. Here, we show that brain-derived proteasomes from SJL mice with experimental autoimmune encephalomyelitis (EAE) in an ubiquitin-independent manner generate significantly increased amounts of myelin basic protein peptides that induces cytotoxic lymphocytes to target mature oligodendrocytes ex vivo. Ten times enhanced release of immunogenic peptides by cerebral proteasomes from EAE-SJL mice is caused by a dramatic shift in the balance between constitutive and β1ihigh immunoproteasomes in the CNS of SJL mice with EAE. We found that during EAE, β1i is increased in resident CNS cells, whereas β5i is imported by infiltrating lymphocytes through the blood–brain barrier. Peptidyl epoxyketone specifically inhibits brain-derived β1ihigh immunoproteasomes in vitro (kobs/[I] = 240 M−1s−1), and at a dose of 0.5 mg/kg, it ameliorates ongoing EAE in vivo. Therefore, our findings provide novel insights into myelin metabolism in pathophysiologic conditions and reveal that the β1i subunit of the immunoproteasome is a potential target to treat autoimmune neurologic diseases.—Belogurov Jr., A., Kuzina, E., Kudriaeva, A., Kononikhin, A., Kovalchuk, S., Surina, Y., Smirnov, I., Lomakin, Y., Bacheva, A., Stepanov, A., Karpova, Y., Lyupina, Y., Kharybin, O., Melamed, D., Ponomarenko, N., Sharova, N., Nikolaev, E., Gabibov, A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity.
Collapse
Affiliation(s)
- Alexey Belogurov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ekaterina Kuzina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Anna Kudriaeva
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexey Kononikhin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Sergey Kovalchuk
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yelena Surina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ivan Smirnov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yakov Lomakin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Anna Bacheva
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexey Stepanov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yaroslava Karpova
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Yulia Lyupina
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Oleg Kharybin
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Dobroslav Melamed
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Natalia Ponomarenko
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Natalia Sharova
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Eugene Nikolaev
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| | - Alexander Gabibov
- *Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia; Kazan Federal University, Kazan, Republic of Tatarstan, Russia; Institute of Gene Biology, Russian Acedemy of Sciences, Moscow, Russia; Chemistry Department of Moscow State University, Moscow, Russia; Moscow Institute of Physics and Technology, Dolgoprudnyi, Russia; Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow, Russia; Research Institute of Physico-Chemical Medicine, Moscow, Russia; **Institute of Developmental Biology, Russian Academy of Sciences, Moscow, Russia; Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, Russia; and Assaf Harofeh Medical Center, Zerifin, Israel
| |
Collapse
|
19
|
Belogurov A, Kudriaeva A, Kuzina E, Smirnov I, Bobik T, Ponomarenko N, Kravtsova-Ivantsiv Y, Ciechanover A, Gabibov A. Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradation. J Biol Chem 2014; 289:17758-66. [PMID: 24739384 PMCID: PMC4067209 DOI: 10.1074/jbc.m113.544247] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
The vast majority of cellular proteins are degraded by the 26S proteasome after their ubiquitination. Here, we report that the major component of the myelin multilayered membrane sheath, myelin basic protein (MBP), is hydrolyzed by the 26S proteasome in a ubiquitin-independent manner both in vitro and in mammalian cells. As a proteasomal substrate, MBP reveals a distinct and physiologically relevant concentration range for ubiquitin-independent proteolysis. Enzymatic deimination prevents hydrolysis of MBP by the proteasome, suggesting that an abnormally basic charge contributes to its susceptibility toward proteasome-mediated degradation. To our knowledge, our data reveal the first case of a pathophysiologically important autoantigen as a ubiquitin-independent substrate of the 26S proteasome.
Collapse
Affiliation(s)
- Alexey Belogurov
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia, the Institute of Gene Biology, Russian Academy of Sciences, 117334 Moscow, Russia
| | - Anna Kudriaeva
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia
| | - Ekaterina Kuzina
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia, the Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia, and
| | - Ivan Smirnov
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia, the Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia, and
| | - Tatyana Bobik
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia
| | - Natalia Ponomarenko
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia
| | - Yelena Kravtsova-Ivantsiv
- the Cancer and Vascular Biology Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 31096, Israel
| | - Aaron Ciechanover
- the Cancer and Vascular Biology Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 31096, Israel
| | - Alexander Gabibov
- From the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117871 Moscow V-437, Russia, the Institute of Gene Biology, Russian Academy of Sciences, 117334 Moscow, Russia, the Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia, and
| |
Collapse
|
20
|
Ponomarenko N, Chatziefthimiou SD, Kurkova I, Mokrushina Y, Mokrushina Y, Stepanova A, Smirnov I, Avakyan M, Bobik T, Mamedov A, Mitkevich V, Belogurov A, Fedorova OS, Dubina M, Golovin A, Lamzin V, Friboulet A, Makarov AA, Wilmanns M, Gabibov A. Role of κ→λ light-chain constant-domain switch in the structure and functionality of A17 reactibody. Acta Crystallogr D Biol Crystallogr 2014; 70:708-19. [PMID: 24598740 PMCID: PMC3949517 DOI: 10.1107/s1399004713032446] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/19/2013] [Accepted: 11/27/2013] [Indexed: 11/10/2022]
Abstract
The engineering of catalytic function in antibodies requires precise information on their structure. Here, results are presented that show how the antibody domain structure affects its functionality. The previously designed organophosphate-metabolizing reactibody A17 has been re-engineered by replacing its constant κ light chain by the λ chain (A17λ), and the X-ray structure of A17λ has been determined at 1.95 Å resolution. It was found that compared with A17κ the active centre of A17λ is displaced, stabilized and made more rigid owing to interdomain interactions involving the CDR loops from the VL and VH domains. These VL/VH domains also have lower mobility, as deduced from the atomic displacement parameters of the crystal structure. The antibody elbow angle is decreased to 126° compared with 138° in A17κ. These structural differences account for the subtle changes in catalytic efficiency and thermodynamic parameters determined with two organophosphate ligands, as well as in the affinity for peptide substrates selected from a combinatorial cyclic peptide library, between the A17κ and A17λ variants. The data presented will be of interest and relevance to researchers dealing with the design of antibodies with tailor-made functions.
Collapse
Affiliation(s)
- Natalia Ponomarenko
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Spyros D. Chatziefthimiou
- European Molecular Biology Laboratory, Hamburg Unit, c/o DESY, Notkestrasse 85, 22603 Hamburg, Germany
| | - Inna Kurkova
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Yuliana Mokrushina
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Yuliana Mokrushina
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Anastasiya Stepanova
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Ivan Smirnov
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Marat Avakyan
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Tatyana Bobik
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Azad Mamedov
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
| | - Vladimir Mitkevich
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - Alexey Belogurov
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
- Institute of Gene Biology, Moscow 117334, Russian Federation
| | - Olga S. Fedorova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk 630090, Russian Federation
| | - Michael Dubina
- St Petersburg Academic University, St Petersburg 194021, Russian Federation
| | - Andrey Golovin
- Lomonosov Moscow State University, Moscow 119991, Russian Federation
| | - Victor Lamzin
- European Molecular Biology Laboratory, Hamburg Unit, c/o DESY, Notkestrasse 85, 22603 Hamburg, Germany
| | - Alain Friboulet
- Université de Technologie de Compiègne, Unité Mixte de Recherche 6022, Centre National de la Recherche Scientifique, 60205 Compiègne, France
| | - Alexander A. Makarov
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russian Federation
| | - Matthias Wilmanns
- European Molecular Biology Laboratory, Hamburg Unit, c/o DESY, Notkestrasse 85, 22603 Hamburg, Germany
| | - Alexander Gabibov
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117871, Russian Federation
- Institute of Gene Biology, Moscow 117334, Russian Federation
- Lomonosov Moscow State University, Moscow 119991, Russian Federation
| |
Collapse
|
21
|
Smirnov I, Belogurov A, Friboulet A, Masson P, Gabibov A, Renard PY. Strategies for the selection of catalytic antibodies against organophosphorus nerve agents. Chem Biol Interact 2012; 203:196-201. [PMID: 23123255 DOI: 10.1016/j.cbi.2012.10.011] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2012] [Revised: 10/12/2012] [Accepted: 10/16/2012] [Indexed: 01/25/2023]
Abstract
Among the strategies aimed at biocompatible means for organophosphorus nerve agents neutralization, immunoglobulins have attracted attention in the 1990's and 2000's both for their ability to immobilize the toxicants, but also for their ability to be turned into enzymatically active antibodies known as catalytic antibodies or abzymes (antibodies--enzymes). We will present here a critical review of the successive strategies used for the selection of these nerve agent-hydrolyzing abzymes, based on hapten design, namely antibodies raised against a wide variety of transition state analogs, and eventually the strategies based on anti-idiotypic antibodies and reactibodies.
Collapse
Affiliation(s)
- Ivan Smirnov
- MM Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | | | | | | | | | | |
Collapse
|
22
|
Belogurov A, Smirnov I, Ponomarenko N, Gabibov A. Antibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality. FEBS Lett 2012; 586:2966-73. [PMID: 22841717 DOI: 10.1016/j.febslet.2012.07.046] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Revised: 07/18/2012] [Accepted: 07/18/2012] [Indexed: 10/28/2022]
Abstract
The unique hypervariability of the immunoglobulin (Ig) superfamily provides a means to create both binding and catalytic antibodies with almost any desired specificity and activity. The diversity of antigens and concept of adaptive response suggest that it is possible to find an antigen pair to any raised Ig. In the current review we discuss combinatorial approaches, which makes it possible to obtain an antibody with predefined properties, followed by 3D structure-based rational design to enhance or dramatically change its characteristics. A similar strategy, but applied to the second partner of the antibody-antigen pair, may result in selection of complementary substrates to the chosen Ig. Finally, 2D screening may be performed solving the "Chicken and Egg" problem when neither antibody nor antigen is known.
Collapse
Affiliation(s)
- Alexey Belogurov
- M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry RAS, Moscow, Russia
| | | | | | | |
Collapse
|
23
|
Abstract
The immunoglobulin molecule is a perfect template for the de novo generation of biocatalytic functions. Catalytic antibodies, or abzymes, obtained by the structural mimicking of enzyme active sites have been shown to catalyze numerous chemical reactions. Natural enzyme analogs for some of these reactions have not yet been found or possibly do not exist at all. Nowadays, the dramatic breakthrough in antibody engineering and expression technologies has promoted a considerable expansion of immunoglobulin's medical applications and is offering abzymes a unique chance to become a promising source of high-precision "catalytic vaccines." At the same time, the discovery of natural abzymes on the background of autoimmune disease revealed their beneficial and pathogenic roles in the disease progression. Thus, the conflicting Dr. Jekyll and Mr. Hyde protective and destructive essences of catalytic antibodies should be carefully considered in the development of therapeutic abzyme applications.
Collapse
Affiliation(s)
- Alexey Belogurov
- Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, Moscow 117997, Russia
| | | | | | | |
Collapse
|
24
|
Stepanova V, Bobik A, Bibilashvily R, Belogurov A, Rybalkin I, Domogatsky S, Little PJ, Goncharova E, Tkachuk V. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain. FEBS Lett 1997; 414:471-4. [PMID: 9315743 DOI: 10.1016/s0014-5793(97)00993-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We defined the role of urokinase plasminogen activator (uPA) and its growth factor-like domain (GFD) in stimulating smooth muscle cell (SMC) migration. Recombinant uPA (r-uPA) stimulated migration approximately 3-fold whilst the recombinant uPA mutant containing an altered GFD (r-uPAmut) was ineffective. Both uPA variants bound to the same high affinity receptor in a competitive manner. FGF-2- and PDGF-BB-induced migration was also dependent on uPA, their effects being antagonized by addition of a uPA-neutralizing antibody or the r-uPAmut. Thus r-uPA is chemotactic for SMC and stimulation of cell migration by PDGF-BB and FGF-2 is dependent on uPA. The GFD of uPA is essential for its chemotactic effects.
Collapse
Affiliation(s)
- V Stepanova
- Laboratory of Molecular Endocrinology, Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia
| | | | | | | | | | | | | | | | | |
Collapse
|